مركـز الكويـت لمكافحـة السرطـان
Kuwait Cancer Control Center

RIBOciclib (Kisqali®)

RBO-000000-04-CN-BR

Ministry of Health

Name: **File #:** **Ht (cm):**
Nationality: **Civil ID:** **Wt (Kg):**
Gender/Age: **DOB:** **BSA (m²):**

Indication(s): HR +ve breast cancer, Neoadjuvant / Adjuvant / Palliative.
Central line: ☐ Available ☐ NA **Allergies:** ☐ NKA ☐ Yes, specify; _____

Standard Protocol:

DRUG	DOSE	ADMINISTRATION	DAYS
RIBOciclib	600 mg PO daily	May take with or without food.	D1 - 21
To be repeated every 4 weeks until disease progression or intolerable toxicity.			

Special instructions: In case of missed dose or vomiting, don't take an additional dose and resume doseing with the next scheduled daily dose.
Avoid concomitant use with strong CYP3A inhibitors and consider an alternative concomitant medication with less potential for CYP3A inhibition.
If a strong CYP3A inhibitor must be coadministered, reduce the RIBOciclib dose to 400 mg/day.
If the strong inhibitor is discontinued, change the RIBOciclib dose (after at least 5 half -lives of the strong CYP3A inhibitor) to the dose used prior to the initiation of the strong CYP3A inhibitor.

Treatment Description:

Cycle	Day	Date	RIBOciclib	Physician	Consultant
C# __	D1 - 21				
C# __	D1 - 21				
C# __	D1 - 21				
C# __	D1 - 21				
C# __	D1 - 21				
C# __	D1 - 21				
C# __	D1 - 21				

Important Notes:
Reported grade 3/4 toxicities: ☐ None ☐ Hematological ☐ Non-Hematological
If yes; Did it indicate hospitalization? ☐ Yes ☐ No
Did it indicate chemo-delay for ≥ 7 days? ☐ Yes ☐ No
Did it indicate dose reduction? ☐ Yes ☐ No
Did it indicate G-CSF support? ☐ Yes ☐ No